We Can Help The costs of mesothelioma can be overwhelming. They can include income loss, expensive treatments that may not be covered by health insurance, plus pain and suffering for you and for your family. Because the disease is preventable – and because it is usually caused by someone else’s negligence – legal options may be available to help regain these costs.
Asbestos lawyers focus their practice on knowledgeably and effectively bringing to justice companies that exposed employees and the public to asbestos products.
A mesothelioma attorney can help you consider your options and file a claim against the company responsible for your asbestos-related illness. More than one company may be responsible. A mesothelioma attorney identifies all companies at fault.
Mesothelioma lawsuits have helped thousands of people receive financial assistance. A lawsuit can result in much-needed money to help reduce financial hardships during an illness and can also provide a more stable future for your loved ones. A lawyer specializing in asbestos litigation can help you seek compensation for expenses related to illness caused by asbestos exposure.
|
|
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine. The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave […]
The post Phase I Trial Improves Mesothelioma Survival More Than 200% appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine. The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave […]
The post Early Mesothelioma Vaccine Testing Shows Promise appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
Results of a new phase 3 clinical trial published in the Journal of Clinical Oncology indicate that a chemoimmunotherapy regimen combining chemotherapy with immunotherapy drugs improves patient survival more than chemotherapy alone for pleural mesothelioma. Study researchers used pembrolizumab (Keytruda) alongside platinum and pemetrexed chemotherapy. Christina S. Baik, MD, MPH, reviewed the phase 3 trial […]
The post Trial Shows Keytruda With Chemotherapy Superior to Chemo Alone appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
For patients with mesothelioma cancer, immunotherapy is a promising new field. Results from a recent study at Rice University in Houston are exciting. Researchers are looking at ways the natural immune system can help fight this cancer. The study examined the therapeutic effects of interleukin 2, a form of immunotherapy for mesothelioma. IL2 is a […]
The post Mesothelioma Treatment Uses Natural Immune Cells appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
Patients with recurrent mesothelioma cancer often have few options. A new study by the Hyogo College of Medicine in Japan may have a potential answer. This study tested the safety and efficacy of two drugs following mesothelioma surgery after cancer recurrence. The combination of immunotherapy drugs nivolumab and ipilimumab, known by the brand names Opdivo […]
The post Study Shows Opdivo, Yervoy Effective After Mesothelioma Surgery appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
An immunotherapy combination given before aggressive surgery has shown impressive effectiveness in extending survival for pleural mesothelioma patients in a recent phase II clinical trial at Baylor College of Medicine. The combination of immune checkpoint inhibitors durvalumab and tremelimumab showed an ability to effectively alter the intratumoral immune system and make surgery more effective. This […]
The post Mesothelioma Surgery With Immunotherapy Proves Effective in Study appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
Patients with unresectable pleural mesothelioma cancer throughout the United Kingdom will now have the immunotherapy combination of Opdivo and Yervoy as an option after its recent approval by the National Health Service for first-line treatment. The long-awaited approval comes almost two years after the U.S. Food and Drug Administration granted a similar approval of Opdivo […]
The post UK Approves Opdivo/Yervoy Immunotherapy for Pleural Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
The 21st Century Cures Act has passed in both the House and Senate and will provide billions of dollars for researching cancer and other deadly diseases. […]
PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients. […]
PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients. […]
Amazon and Microsoft have teamed up with the National Cancer Institute to develop a repository for genome data. Read more at Mesothelioma Cancer Alliance. […]
Amazon and Microsoft have teamed up with the National Cancer Institute to develop a repository for genome data. Read more at Mesothelioma Cancer Alliance. […]
A new clinical trial at Baylor University’s Mesothelioma Treatment Center is looking at the effectiveness of using immunotherapy before surgery. […]
The U.S. Food and Drug Administration (FDA) has approved the drug Keytruda for patients with head and neck squamous cell carcinoma (HNSCC). […]
The immunotherapy drug avelumab showed promising results in a recent phase I clinical trial for malignant mesothelioma, raising hopes as a future second-line therapy. The clinical trial included 53 patients with pleural or peritoneal mesothelioma. It was part of the JAVELIN development program for avelumab, a series of clinical studies testing the drug on about…
The post Immunotherapy Trial for Mesothelioma Shows Early Promise appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]
|
